APA (7th ed.) Citation

John, N., Pathmanandavel, S., Crumbaker, M., Counter, W., Ho, B., Yam, A. O., . . . Emmett, L. (2022). 177Lu-PSMA SPECT Quantitation at 6 Weeks (dose 2) Predicts Short Progression Free Survival for Patients Undergoing Lu PSMA I&T Therapy. Journal of Nuclear Medicine, 63(10), 1. https://doi.org/10.2967/jnumed.122.264677

Chicago Style (17th ed.) Citation

John, Nikeith, et al. "177Lu-PSMA SPECT Quantitation at 6 Weeks (dose 2) Predicts Short Progression Free Survival for Patients Undergoing Lu PSMA I&T Therapy." Journal of Nuclear Medicine 63, no. 10 (2022): 1. https://doi.org/10.2967/jnumed.122.264677.

MLA (9th ed.) Citation

John, Nikeith, et al. "177Lu-PSMA SPECT Quantitation at 6 Weeks (dose 2) Predicts Short Progression Free Survival for Patients Undergoing Lu PSMA I&T Therapy." Journal of Nuclear Medicine, vol. 63, no. 10, 2022, p. 1, https://doi.org/10.2967/jnumed.122.264677.